This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. IGC Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.021. IGC Pharma's 10-Year median PS Ratio is 9.5238. Therefore, the Median PS Value for today is $0.20.
As of today (2024-04-24), IGC Pharma's share price is $0.4566. IGC Pharma's Median PS Value is $0.20. Therefore, IGC Pharma's Price to Median PS Value for today is 2.28.
The historical rank and industry rank for IGC Pharma's Median PS Value or its related term are showing as below:
IGC'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.4 Med: 6.71 Max: 74
Current: 2.28
During the past 13 years, the highest Price to Median PS Value of IGC Pharma was 74.00. The lowest was 1.40. And the median was 6.71.
IGC's Price-to-Median-PS-Value is ranked worse than 89.15% of 258
companies
in the Biotechnology industry
Industry Median: 0.665
vs IGC: 2.28
IGC Pharma Median PS Value Historical Data
The historical data trend for IGC Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Price-to-Median-PS-Value Distribution
For the Biotechnology industry and Healthcare sector, IGC Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Price-to-Median-PS-Value falls into.
IGC Pharma Median PS Value Calculation
IGC Pharma's Median PS Value for today is calculated as
10-Year Median PS Ratio is 9.5238.
IGC Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (AMEX:IGC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
IGC Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.4566
/
0.20
=
2.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma Median PS Value Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your 